KalVista Pharmaceuticals Inc. (NASDAQ: KALV), a clinical-stage biotechnology company focused on hereditary angioedema and protease inhibitor therapies, is experiencing significant short-selling pressure, with short interest reported at roughly 40% of its public float in mid-January 2026. With nearly 20 million shares sold short and a days-to-cover ratio exceeding 11 based on average trading volume, the stock has seen continued price fluctuations in early February. The concentration of short positioning has raised concerns about whether aggressive trading dynamics may be contributing to heightened volatility in the mid-cap biotech space.
Despite advancing its pipeline, including potential regulatory milestones tied to sebetralstat (EKTERLY), sustained high short interest can weigh on investor sentiment and amplify downside pressure during critical development stages. The situation highlights broader concerns about how concentrated bearish positioning may influence trading behavior and capital market dynamics for emerging biopharmaceutical companies operating in high-risk, catalyst-driven sectors.
To learn more, read the full Economic Sentinel article at https://ibn.fm/usZBQ
Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected
About Economic Sentinel
Economic Sentinel, in partnership with IBN and USO.live, provides issuers with robust protection against market manipulation, particularly naked shorting, which introduces synthetic shares, depresses stock prices, reduces shareholder value, and jeopardizes company stability. C-level executives at affected issuers: if hedge funds, dark pools, chat rooms, and brokers are impacting your market cap through spoofing, disinformation campaigns, failures to deliver (FTDs), or DTC over-issuances, we equip you with Arbiter AI—our advanced proprietary system that identifies naked shorts, uncovers participants, and compiles comprehensive evidence dossiers for submission to the SEC, FINRA, DOJ, and state regulators. We execute targeted responses, including investigative exposés and referrals to press outlets for syndication, resolving issues in days rather than years, preventing costly class-action lawsuits, facilitating short covers, and recovering significant valuation to strengthen your position. Backed by a proven track record through our four-phase process and continuous monitoring, we guarantee effective results to mitigate shorts, ensure market fairness, and support stock appreciation.
For more information, visit www.EconomicSentinel.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]